Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Johnson & Johnson (JNJ) and Amicus (FOLD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Maravai Lifesciences Holdings (MRVI – Research Report), Johnson & Johnson (JNJ – Research Report) and Amicus (FOLD – Research Report).

Maravai Lifesciences Holdings (MRVI)

Bank of America Securities analyst Michael Ryskin maintained a Hold rating on Maravai Lifesciences Holdings today and set a price target of $12.00. The company’s shares closed last Thursday at $9.60, close to its 52-week low of $9.09.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 4.2% and a 55.3% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Phibro Animal Health, and Idexx Laboratories.

Currently, the analyst consensus on Maravai Lifesciences Holdings is a Moderate Buy with an average price target of $12.53.

See today’s best-performing stocks on TipRanks >>

Johnson & Johnson (JNJ)

In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Hold rating on Johnson & Johnson, with a price target of $180.00. The company’s shares closed last Thursday at $156.88.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.0% and a 50.6% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Rani Therapeutics Holdings, and Turnstone Biologics Corp.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $178.64.

Amicus (FOLD)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Amicus yesterday and set a price target of $19.00. The company’s shares closed last Thursday at $11.86.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 5.5% and a 47.5% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Apellis Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Amicus is a Strong Buy with an average price target of $17.50, a 37.7% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRVI:

• Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100
• Maravai LifeSciences to Host 2023 Investor R&D Day
• Cygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit
• Maravai LifeSciences Announces August 2023 Investor Conference Schedule
• Maravai LifeSciences trading resumes